The Lakers changed hands at a $12.5 billion valuation this week while KKR simultaneously closed a $5.7 billion take-private of Integer Holdings, a medical device manufacturer. The timing is not accidental. Both transactions reflect private equity's deployment thesis for 2025: controlled assets with pricing power in sectors where public comps trade at discounts to intrinsic value.

The Lakers deal represents a 22% premium to the franchise's last private transaction in 2021 and establishes a new benchmark for NBA valuations. The buyer group includes existing institutional holders rotating from minority to control stakes, a structure that bypassed competitive auction dynamics. Integer, meanwhile, traded at 14.2x forward EBITDA before KKR's offer, a 31% discount to its three-year average multiple. KKR is paying $4.3 billion in equity after debt assumption, betting that healthcare supply chain consolidation will drive margin expansion outside public market scrutiny.

The overlap matters because both sectors—sports franchises and healthcare infrastructure—offer the same fundamental appeal to allocators: revenue streams insulated from consumer discretionary cycles, limited competitive entry, and exit optionality through either strategic sale or public re-listing. Sports franchises generate media rights fees indexed to inflation and locked in through 2030 for major leagues. Integer's implantable cardiac devices carry 80%+ gross margins and serve a demographic tailwind that compounds through 2040. Neither asset class requires growth capital to generate returns; both produce cash immediately.

The Ascension health system's expansion of its PE joint venture structure, announced within 72 hours of the Integer deal, signals the third leg of this deployment pattern. Ascension is adding $2.1 billion in private equity partnerships across ambulatory surgery centers and imaging facilities, a model that allows non-profit systems to monetize infrastructure without relinquishing care delivery control. That structure now governs 18% of Ascension's revenue base, up from 11% in 2023. The convergence of sports, medical devices, and healthcare real estate in the same week is not thematic investing—it is capital flowing toward assets that generate predictable cash in environments where public equity volatility creates valuation dislocations.

Allocators should watch three follow-on events. First, the NBA's next media rights auction in late 2025 will test whether the Lakers' valuation holds as a comp for other franchises entering sale processes. Second, Integer's Q2 earnings under KKR ownership, expected in August, will reveal whether the thesis depends on operational improvements or multiple arbitrage. Third, Ascension's partnership model will either expand to other non-profit systems by year-end or stall if regulatory scrutiny around PE-healthcare ties intensifies at the state level.

The Lakers valuation is now higher than the enterprise value of 23 S&P 500 companies. That comparison is the signal.